Qualigen Therapeutics, Inc.
QLGN
$3.11
$0.103.32%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 50.93% | 54.49% | 47.15% | 61.55% | -- |
| Total Depreciation and Amortization | -- | -- | -- | 50.00% | -- |
| Total Amortization of Deferred Charges | -58.39% | -13.81% | -80.56% | -- | -- |
| Total Other Non-Cash Items | -88.83% | -1.45% | 158.80% | -212.68% | -- |
| Change in Net Operating Assets | -83.41% | -58.82% | 28.50% | -52.83% | -- |
| Cash from Operations | -293.60% | 49.65% | 70.25% | -153.46% | 129.22% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -129.57% | 823.14% | -- | 196.32% | -- |
| Cash from Investing | -129.57% | 823.14% | -- | 196.32% | 37,507.08% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -354.55% | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 854.39% | -- | -- | -103.79% | -13,433.33% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -94.14% | 100.84% | 88.45% | -1,431.94% | 247.08% |
